Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stiven Roytman

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Nutrients|July 14, 2023
Ketogenic-Mimicking Diet as a Therapeutic Modality for Bipolar Disorder: Biomechanistic Rationale and Protocol for a Pilot Clinical TrialJeffrey L B Bohnen, Travis P Wigstrom, Alexis M Griggs, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 21, 2025
Dietary tributyrin supplementation in Parkinson's disease: An open-label target engagement studyJeffrey L B Bohnen, Stiven Roytman, Travis P Wigstrom, et al.
Nature Communications|July 2, 2025
A multicenter longitudinal study of cholinergic subgroups in Parkinson diseaseNicolaas I Bohnen, Stiven Roytman, Sygrid van der Zee, et al.
Research Square|February 12, 2026
Cholinergic substrates of gait and postural impairments in Progressive Supranuclear PalsyPrabesh Kanel, Giulia Carli, Stiven Roytman, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Nutrients|July 14, 2023
Ketogenic-Mimicking Diet as a Therapeutic Modality for Bipolar Disorder: Biomechanistic Rationale and Protocol for a Pilot Clinical TrialJeffrey L B Bohnen, Travis P Wigstrom, Alexis M Griggs, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 21, 2025
Dietary tributyrin supplementation in Parkinson's disease: An open-label target engagement studyJeffrey L B Bohnen, Stiven Roytman, Travis P Wigstrom, et al.
Nature Communications|July 2, 2025
A multicenter longitudinal study of cholinergic subgroups in Parkinson diseaseNicolaas I Bohnen, Stiven Roytman, Sygrid van der Zee, et al.
Research Square|February 12, 2026
Cholinergic substrates of gait and postural impairments in Progressive Supranuclear PalsyPrabesh Kanel, Giulia Carli, Stiven Roytman, et al.
Pageof 4